← back to search

Julián Torre‐Cisneros

Instituto de Salud Carlos III · ES
Area of research
Epidemiology · Molecular Medicine
Research interest
Research interests include Cytomegalovirus and herpesvirus research, Antibiotic Resistance in Bacteria, Herpesvirus Infections and Treatments, and Nosocomial Infections in ICU.
h-index
48
citations
9,881
works
224
NIH funding
primary concept
Medicine
email

Recent publications

The Troll Is Weakened but Not yet Defeated: An Update on Cytomegalovirus Management in Transplantation From the International CMV Symposium 2025.
2026cited by 0position: contributordoi
Experience with isavuconazole in lung transplant recipients with <i>Aspergillus</i> isolation in respiratory tract specimens: A multicenter, observational study.
2026cited by 0position: contributordoi
Cost-Effectiveness Analysis of Aztreonam-Avibactam Compared with Colistin Plus Meropenem in Treating Metallo-Beta-Lactamase-Producing Enterobacterales Infections in Spain.
2026cited by 0position: contributordoi
De Novo Cancer in Liver Transplant Patients With Human Immunodeficiency Virus Infection: A Multicenter Nationwide Cohort Study.
2026cited by 0position: contributordoi
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.
2025cited by 62position: contributordoi
Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study).
2025cited by 7position: contributordoi
Safety and efficacy of immunoguided prophylaxis for cytomegalovirus disease in low-risk lung transplant recipients in Spain: a multicentre, open-label, randomised, phase 3, noninferiority trial
The Lancet Regional Health - Europe 2025cited by 3position: contributordoi
Identification and validation of clinical phenotypes in <i>Staphylococcus aureus</i> bloodstream infection and their association with mortality (FEN-AUREUS study).
2025cited by 3position: contributordoi
Immune Monitoring Assays: Predicting Cytomegalovirus and Other Infections in Solid Organ Transplant Recipients.
2025cited by 1position: contributordoi
Efficacy of high doses of intravenous fosfomycin for treatment of urinary tract infection caused by KPC carbapenemase-producing Klebsiella pneumoniae: An observational study.
2025cited by 1position: contributordoi
Quantifying Gamma-Interferon from CMV-Specific CD8+ T Cells Defines Protection Against Clinically Significant CMV Infection in Solid Organ Transplant Recipients: The Quanti-CMV Score.
2025cited by 1position: contributordoi
Compassionate Use of Encapsulated MKB-01 Fecal Microbiota Transplantation for Recurrent <i>Clostridioides difficile</i> Infection: A Single-Center Experience.
2025cited by 0position: contributordoi
Impact of CMV-specific immune reconstitution at the end of letermovir prophylaxis on the development of late cytomegalovirus infection in haematopoietic stem cell transplant recipients (INMUNOEND): a protocol for a prospective, observational, multicentre study.
2025cited by 0position: contributordoi
In Vitro Activity of Delafloxacin Against <i>Corynebacterium</i> spp.
2025cited by 0position: contributordoi
Incidence, clinical and genomic trends of hospital- and Non-hospital-onset KPC-producing Klebsiella pneumoniae infections before and during the COVID-19 era: a ten-year interrupted time series study.
2025cited by 0position: contributordoi
UCO-IMIBIC Consensus for the Definition of Competencies Related to Human Clinical Research in Higher Education Life Sciences Degree Programs (Preprint)
2025cited by 0position: contributordoi
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
The Lancet Infectious Diseases 2024cited by 91position: middledoi
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
2024cited by 24position: contributordoi
Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update.
2024cited by 13position: contributordoi
Slaying the "Troll of Transplantation"-new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023.
2024cited by 12position: contributordoi
Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study.
2024cited by 12position: contributordoi
Invasive aspergillosis in liver transplant recipients in the current era
American Journal of Transplantation 2024cited by 8position: contributordoi
Invasive aspergillosis in liver transplant recipients in the current era
American Journal of Transplantation 2024cited by 7position: middledoi
Isavuconazole Versus Voriconazole as the First-line Therapy for Solid Organ Transplant Recipients With Invasive Aspergillosis: Comparative Analysis of 2 Multicenter Cohort Studies.
2024cited by 5position: contributordoi
Long-Term Clinical and Ecological Impact of an Antimicrobial Stewardship Program on the Incidence of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Infections in a High-Endemic Hospital.
2024cited by 5position: contributordoi
Recurrent Clostridioides difficile infections in solid organ transplant recipients: The international CALIPSO study.
2024cited by 5position: contributordoi
QuantiFERON-CMV assay by chemiluminescence immunoassay: Is it more suitable for real-live monitoring of transplant patients?
2024cited by 4position: contributordoi
COVID-19 clinical phenotypes in vaccinated and nonvaccinated solid organ transplant recipients: a multicenter validation study.
2024cited by 3position: contributordoi
How can we optimize the diagnostic and therapeutic approach to pneumonia? Expert opinion-based recommendations.
2024cited by 2position: contributordoi
Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA).
2023cited by 47position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 39 papers (2020–2026)Jesús Rodríguez-Baño · Instituto de Investigación Biomédica de Málaga24 papers (2019–2025)Elena Pérez-Nadales · Elsevier, Inc.11 papers (2019–2025) · 11 papers (2020–2025)Luis Martínez-Martínez · Instituto de Salud Carlos III10 papers (2021–2025)Jordi Carratala · Centro de Investigación Biomédica en Red de Salud Mental10 papers (2019–2024)Elisa Cordero · Junta de Andalucía9 papers (2019–2026)Patricia Muñóz · Universidad Complutense de Madrid7 papers (2020–2024)José Antonio Lepe · Instituto de Salud Carlos III7 papers (2019–2022)Elisa Ruiz-Arabi · Universitat Pompeu Fabra7 papers (2024–2026)Juan José Castón · Hospital Universitario Reina Sofía7 papers (2024–2025)José Miguel Cisneros · Sociedad Española de Cardiología7 papers (2019–2024)Mario Fernández‐Ruiz · Elsevier, Inc.6 papers (2019–2026)Rafael Cantón · Madrid Institute for Advanced Studies6 papers (2019–2024) · 5 papers (2020–2024)Alejandra M. Natera · Universidad de Córdoba5 papers (2022–2025)Angela Cano · Instituto de Salud Carlos III5 papers (2024–2025)Isabel Machuca · Spanish Network for Research in Infectious Diseases (REIPI RD12/0015 and RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.5 papers (2022–2025)Germán Bou · Universidade da Coruña4 papers (2019–2022)Ferran Navarro · Institut de Recerca Sant Pau4 papers (2019–2020)